Active ingredient: immunoglobulin normal humanֲ -ֲ 0.5G/10ML
|Shelf life||presentation||Packaging material|
|24 months||10 ML / 0.5g||Vial glass type II|
|24 months||50 ML ֲ / 2.5g||Bottle glass type II|
|24 months||100 ML / 5g||Bottle glass type II|
|24 months||200 ML / 10g||Bottle glass type II|
|24 months||400 ML / 20g||Bottle glass type II|
Replacement therapy in:
Primary immunodeficiency syndroms such as:
Congenital agammaglobulinaemia and hypogammaglobulinaemia
Common variable immunodeficiency
Severe combined immunodeficiency
Wiskott Aldrich syndrome
Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.
Children with congenital AIDS and recurrent infections.
Idiopathic thrombocytopenicpurpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count.
Guillain Barre’ Syndrome.
Allogeneic bone marrow transplantation.
IVIG stands for intravenous immune globulin; it is a sterile solution of concentrated antibodies extracted from healthy donors which is administered into a vein. IVIG is used to treat disorders of the immune system or to boost immune response to serious illness, and to treat immuno-suppressed recipients of bone marrow transplants.ֲ Antibodies are responsible for defending our bodies from pathogens, such as viruses and bacteria.
There is a highly specialized and lengthy process used to manufacture IVIG. It begins in blood centers across the country where tens of thousands of healthy individuals donate their plasma (the portion of the blood where the immune globulins and other blood proteins are contained). The plasma from all of these individuals is then pooled together, and then chemically treated to isolate the immune globulins and remove any other blood proteins or blood-borne pathogens. The end result is a highly purified immune globulin preparation that is then packaged and ready to be infused.
For more information :